China Shineway Pharmaceutical Group (2877) Stock Overview
An investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People’s Republic of China and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
2877 Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
China Shineway Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$8.29 |
| 52 Week High | HK$10.47 |
| 52 Week Low | HK$7.21 |
| Beta | 0.71 |
| 1 Month Change | 2.73% |
| 3 Month Change | -17.10% |
| 1 Year Change | 0.12% |
| 3 Year Change | 1.72% |
| 5 Year Change | -11.90% |
| Change since IPO | 71.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2877 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 7.2% | 1.9% | 2.1% |
| 1Y | 0.1% | -14.5% | -3.0% |
Return vs Industry: 2877 exceeded the Hong Kong Pharmaceuticals industry which returned -14.5% over the past year.
Return vs Market: 2877 exceeded the Hong Kong Market which returned -3% over the past year.
Price Volatility
| 2877 volatility | |
|---|---|
| 2877 Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 7.6% |
| 10% most volatile stocks in HK Market | 16.3% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2877 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2877's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 2,822 | n/a | www.shineway.com.hk/en/index.aspx |
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People’s Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; and other dosage forms, including pills and tablets; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediatrics, chronic illnesses, and other areas, as well as medication for strengthening the body. It is also involved in the trading of agricultural products.
China Shineway Pharmaceutical Group Limited Fundamentals Summary
| 2877 fundamental statistics | |
|---|---|
| Market cap | HK$6.13b |
| Earnings (TTM) | HK$1.10b |
| Revenue (TTM) | HK$3.63b |
Is 2877 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2877 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.14b |
| Cost of Revenue | CN¥869.21m |
| Gross Profit | CN¥2.27b |
| Other Expenses | CN¥1.32b |
| Earnings | CN¥949.95m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.26 |
| Gross Margin | 72.28% |
| Net Profit Margin | 30.30% |
| Debt/Equity Ratio | 4.0% |
How did 2877 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/15 10:35 |
| End of Day Share Price | 2026/07/15 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
China Shineway Pharmaceutical Group Limited is covered by 18 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Shao | BofA Global Research |
| Shun Kei Law | CCB International Securities Limited |
| Zhishun Siu | CCB International Securities Limited |